Adenosine Therapeutics, LLC

Phase I/II grant awarded to prevent cardiac reperfusion injury

Published in Elder Law Weekly, August 3rd, 2005

Adenosine Therapeutics, LLC, an adenosine drug discovery and development company, announced that it has been awarded a fast track phase I/II Small Business Innovation Research (SBIR) grant from the Department of Health and Human Services at the U.S. National Institutes of Health.

The grant will fund the clinical development of the company's lead compound, ATL-146e, to prevent reperfusion injury. The amount of the award is approximately $2.0 million, and will be used to support the completion of phase I and phase II clinical trials to develop a drug to prevent cardiac reperfusion injury.

"The primary goal of this project is to expedite clinical...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Elder Law Weekly

Source: Elder Law Weekly (2005-08-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry